Today, Lion Biotechnologies’ (LBIO) “Buy” Rating Reaffirm at Roth Capital

Today, Lion Biotechnologies’ (LBIO) “Buy” Rating Reaffirm at Roth Capital

Roth Capital reissued their buy rating on shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) in a research note published on Monday morning. They currently have a $15.00 price objective on the biotechnology company’s stock.

LBIO has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Lion Biotechnologies from a hold rating to a sell rating in a research report on Wednesday, November 9th. Jefferies Group reissued a buy rating and set a $13.00 target price on shares of Lion Biotechnologies in a research report on Monday, November 7th. Cowen and Company reissued a buy rating on shares of Lion Biotechnologies in a research report on Friday, November 4th. Finally, Chardan Capital set a $20.00 target price on shares of Lion Biotechnologies and gave the stock a buy rating in a research report on Sunday, August 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $18.29.

Lion Biotechnologies (NASDAQ:LBIO) opened at 6.95 on Monday. The company’s 50-day moving average price is $6.74 and its 200-day moving average price is $7.62. The firm’s market cap is $431.50 million. Lion Biotechnologies has a 52-week low of $4.24 and a 52-week high of $9.58.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $101,000. Quantitative Investment Management LLC acquired a new stake in Lion Biotechnologies during the second quarter worth $117,000. Stevens Capital Management LP acquired a new stake in Lion Biotechnologies during the third quarter worth $118,000. TD Asset Management Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $123,000. Finally, Geduld E E boosted its stake in Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock worth $123,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 79.62% of the company’s stock.

About Lion Biotechnologies

Related posts

Leave a Comment